The economic burden of idiopathic pulmonary fibrosis in Australia: a cost of illness study.
Ingrid A CoxBarbara de GraaffHasnat AhmedJulie CampbellPetr OtahalTamera J CorteYuben MoodleyNicole GohPeter HopkinsSacha MacanshE Haydn WaltersAndrew J PalmerPublished in: The European journal of health economics : HEPAC : health economics in prevention and care (2022)
This cost-of-illness study provides the first comprehensive assessment of IPF-related direct costs in Australia, identifies the key cost drivers and provides a framework for future health economic analyses. Additionally, it provided insight into the major cost drivers which include antifibrotic medication, hospital admissions and medications related to comorbidities. Our findings emphasize the importance of the appropriate management of comorbidities in the care of people with IPF as this was one of the main reasons for hospitalizations.